Targeted therapies including PARP inhibitors for BRCA1/2 deficient ovarian and more recently breast cancers and PD-1 inhibitors for MMR deficient tumours, were not available until towards the end of era 2 or even era 3 [24, 25]. This evidence concerns the gene BRCA1 and neoplasm.